세계 동물용 신경퇴행성 질환 진단 시장은 2025-2032년의 예측 기간 동안 7.47%의 연평균 복합 성장률(CAGR)을 나타내고, 2024년 4억 달러에서 2032년 7억 1,000만 달러로 성장할 것으로 예측됩니다. 동물용 신경퇴행성 질환 진단 시장은 지속적으로 성장하고 있으며, 그 원인 중 하나는 동물의 신경질환에 대한 인식이 높아지고 조기에 정확한 진단이 필요하기 때문입니다. 인공지능을 이용한 영상진단, MRI를 이용한 휴대용 영상진단, 분자 바이오마커 평가 등 진단의 많은 기술 혁신은 수의학에 큰 의미와 연관성을 가지고 있습니다. 이는 수의사가 인지기능 장애를 포함한 반려동물의 복잡한 질병을 감지, 모니터링, 평가하는 방법에 큰 변화를 가져오고 있습니다. 반려동물 보유율 증가와 사람들이 반려동물과 맺는 정서적 유대감도 전문 의료비 지출 증가에 영향을 미치고 있습니다.
또한, 반려동물 보험과 정부 지원 가축 보험 제도의 확대는 비용과 관련된 장벽을 낮추고 고급 진단에 대한 폭넓은 접근을 가능하게 하고 있습니다. 끊임없는 기술 혁신은 수의학 연구에 대한 투자 증가 및 임상 인프라 개선과 함께 진화하는 이 시장의 미래를 형성하는 데 중요한 역할을 하고 있습니다.
예를 들어, 2024년 10월, 우리엔은 MyVet CT Plus를 출시하였습니다. MyVet CT Plus는 스캔 및 재구성 시간이 대폭 단축되어 촬영 시간이 최대 80% 단축되고, 소형 파충류부터 대형견까지 다양한 동물에 적합한 유연한 시야를 특징으로 하는 스파이럴 리니어형 동물용 CT 스캐너입니다. 보다 쉽게 사용할 수 있습니다.
대상이 되는 모든 지역과 국가에 대해 모든 부문이 제공됩니다.
위에 언급된 회사는 시장 점유율에 따른 순위를 보유하지 않으며, 조사 작업 중 이용 가능한 정보에 따라 변경될 수 있습니다.
Global veterinary neurodegenerative disease diagnostics market is projected to witness a CAGR of 7.47% during the forecast period 2025-2032, growing from USD 0.40 billion in 2024 to USD 0.71 billion in 2032. The veterinary neurodegenerative disease diagnostics market continues to grow in a consistent manner, partially due to the increase in awareness of neurological disorders in animals and the need for early and accurate diagnostics. Many innovations in diagnostics have great significance and relevance to veterinary medicine, such as artificial intelligence-assisted imaging, portable imaging in the form of MRI, and molecular biomarker assessments. This is significantly changing the ways in which veterinarians detect, monitor and assess complex diseases in companion animals including cognitive dysfunction. Increased levels of pet ownership and the emotional bond that people have with their companion animals also influence the increased spending for specialty care.
Additionally, the expansion of pet insurance and government-supported livestock insurance schemes is reducing cost-related barriers and enabling wider access to advanced diagnostics. Continuous technological innovation, combined with growing investment in veterinary research and improved clinical infrastructure, plays a vital role in shaping the future of this evolving market.
For instance, in October 2024, WOORIEN Co., Ltd. launched the MyVet CT Plus, a spiral-linear veterinary CT scanner featuring significantly faster scan and reconstruction times-reducing acquisition by up to 80%-and a flexible field-of-view suitable for animals from small reptiles to large dogs, making advanced imaging more accessible to diverse veterinary practices
Advancements in Diagnostic Technologies Driving Precision in Veterinary Neurodegenerative Disease Diagnostics
Veterinary neurodegenerative diagnostics is rapidly evolving with the integration of advanced technologies. Newer technologies, such as AI based imaging, high field MRI, and biomarker-based testing, will lead to earlier and more precise identification of complex neurological problems. In addition to offering more precise identification of disease, these technologies also provide improved characterization of the disease, assist with planning treatment, and provide ongoing assessment of treatment efficacy. The transition to digital systems and point-of-care diagnostics will enhance accessibility to diagnostics in all aspects of veterinary practice ranging from no/vet to urban/rural contexts. Advanced imaging, specifically MRI has evolved significantly in its ability to assess and identify subtle brain and spinal abnormalities. The ability progressively to document and assess a patient's disease over time will provide the veterinary clinician with substantial insights into disease progression and prognosis. Advances in technology are changing the landscape of veterinary neurology.
For instance, in June 2025, Siemens Healthineers gained FDA clearance for the Magnetom Flow.Ace 1.5 T MRI scanner, developed for both human and veterinary applications. Featuring AI-powered image reconstruction and an energy-efficient CoolDry helium system, the scanner enhances soft-tissue visualization, shortens scan durations, and adapts to diverse animal anatomies, marking a significant advancement in veterinary neurodiagnostic imaging.
Growing Pet Insurance Coverage Fuels Market Expansion
The increasing availability and uptake of pet insurance is one of the most important factors contributing to the growth of the veterinary neurodegenerative disease diagnostics market. Because diagnostic tools like MRIs, CTs, and biomarker tests can be expensive, insurance coverage opens up options for clients without the affordability barrier. Many policies now cover advanced diagnostic services; thus, veterinarians can now recommend full neurological evaluations without excess financial concern. This not only helps pet owners get an early and accurate diagnostic outcome when assessing if neurodegenerative disease is present, insurance had also opened the gate for veterinarians to adopt advanced technology by providing the immediate financial support necessary. The financial resources from insurance have quickened the pace of precision diagnostics and is helping to shape the future of the market.
For instance, in March 2025, according to Press Information Bureau, Government of India Under the National Livestock Mission (NLM), 21.01 lakh livestock animals were insured in the current financial year, supporting access to veterinary diagnostics, including neurodegenerative disease detection, by reducing financial barriers for farmers through demand-driven insurance coverage.
MRI Imaging Leads in Veterinary Neurodegenerative Diagnostics Market
MRI has emerged as the leading diagnostic tool in the veterinary neurodegenerative diagnostics market. As a non-invasive imaging technique, MRI excels at producing high-quality images of the brain and spinal cord, allowing for the identification of various conditions, regardless of their etiology, including cognitive dysfunction, cerebellar abiotrophy and other neurodegenerative diseases. MRI is set apart from other imaging techniques by its exceptional soft tissue contrast and absence of radiation exposure, making it a safer proposition. As a result, veterinary clinics and specialty hospitals are installing MRI systems into their practices to allow for rapid and accurate assessment of animals. The increase in demand for advanced neurological diagnostic testing provided to companion animals (dogs and cats) has further justified the use of MRI in a veterinary setting. With improved technology and availability of high-field MRI systems, this segment continues to gain momentum within the veterinary imaging market.
For instance, in October 2024, InkSpace Imaging LLC introduced the Nuzzle veterinary array, a new and innovative MRI coil that is approved for animal use. This will allow for much clearer, high-resolution images to drive detection and diagnosis of neurological diseases and disorders in the field of veterinary medicine.
North America Leads the Veterinary Neurodegenerative Diagnostics Market
North America holds a dominant position in the veterinary neurodegenerative diagnostics market. The main reason behind this is its well-developed veterinary healthcare system and high awareness among pet owners regarding neurological conditions in animals. The North America region is generally characterized by strong research and development funding, robust regulatory frameworks, strong veterinary healthcare systems, partnerships between academia, diagnostic developers, and commercialization support. The North America region has a large population of companion and performance animals along with an abundance of skilled veterinary professionals. The overall focus of North America is on the early and accurate detection of disease, and it has so far supported and sustained all the necessary elements to lead the way in veterinary neurodegenerative diagnostics.
For instance, in March 2025, NVIDIA Corporation and GE HealthCare Technologies Inc. announced a partnership to develop autonomous diagnostic imaging systems using physical AI. This collaboration leverages simulation and robotics to improve imaging accuracy and efficiency in clinical settings.
Impact of U.S. Tariffs on Veterinary Neurodegenerative Disease Diagnostics Market
Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.
Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries. Companies may select to work with domestic suppliers or alternate suppliers, which affect time.
Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.
Higher prices and lower availability may inhibit any growth of the market in the interim time.
Key Players Landscape and Outlook
The key players operating the market are focusing on innovation, strategic partnerships, and continuing advancements in diagnostics. Their priority is to the develop improved tools for the early detection of neurodegenerative diseases in the veterinary setting. Most of the companies are investing in artificial intelligence and digital image assessment tools to improve accuracy and efficiency of diagnostics. Others are emphasizing point-of-care testing to provide rapid diagnostics in a clinical environment. Many are emphasizing the expansion of laboratory networks as well as the integration of diagnostics with the treatment protocols. Other companies are partnering with research institutions to assess new biomarkers and neuroimaging. The greater usage of cloud-based diagnostic resources is expediting diagnostic workflows and promoting processes that allow data transfer sharing. Thus, the focus is on technological advancement, accessibility, and achieving better diagnostic decisions about difficult neurodegenerative issues in animals.
For instance, in January 2025, Zoetis Inc. launched an enhanced Vetscan Imagyst with 6-in-1 AI-powered diagnostics, including blood, fecal, dermatology, and urine analysis, advancing speed and accuracy in veterinary neuro diagnostics.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.